Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

HER2-positive Early Breast Cancer

Urinary Bladder Neoplasms, Ureteral Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Non-squamous NSCLC

Metastatic Hormone-sensitive Prostate Cancer

Breast Neoplasms

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Breast Neoplasms

Carcinoma, Lung Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Locally Advanced or Metastatic Unresectable Urothelial Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Breast Neoplasms

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Sarcoma

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Esophageal Neoplasms

HER2-positive Early Breast Cancer

Stomach Neoplasms

Metastatic Castrate Resistant Prostate Cancer

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

Parkinson Disease 4, Autosomal Dominant Lewy Body, Nasopharyngeal Neoplasms

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Clinical Trials

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

KEYNOTE-585

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

CheckMate 816

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

PYRAMID-1

CHAARTED

APHINITY

SAPPHIRE

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

VITAL

PRECIOUS

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

TROPiCS-04

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

KEYNOTE-921

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

CheckMate 7DX

PRESIDE

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

EURTAC

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

RATIONALE-303

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

CheckMate 078

FLOT5

TROIKA

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

MK-3475-033

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

FeDeriCa

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

TavIx

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

PRODIGY

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

RANGE

MK-3475-040

Keynote-122

Combination Chemotherapy in Treating Women With Breast Cancer

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

PEONY